Guidant, Medtronic Look To CHF Market To Offset Slowing Of Stent Growth
This article was originally published in The Gray Sheet
Seeing the initial signs of declining stent prices and an uninspiring tachycardia product line-up, investors bypassed 1998's device darlings in 1999 - Medtronic and Guidant - while keeping a close eye on efforts by those companies to develop a potentially lucrative market opportunity in treating congestive heart failure (CHF) patients.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.